# Emerging therapeutic approaches in graves’ ophthalmopathy: an update on pharmacological interventions

## TL;DR

This paper reviews new drug treatments for Graves’ ophthalmopathy, an autoimmune eye disease, focusing on recent advances beyond traditional corticosteroids.

## Contribution

The paper provides an updated overview of novel pharmacological therapies and treatment strategies for active Graves’ ophthalmopathy.

## Key findings

- Targeted therapies like monoclonal antibodies against CD20, IL-6 R, and IGF-1R show promise in treating active Graves’ ophthalmopathy.
- Recent advances in understanding the disease's immunopathogenesis have led to more effective and individualized treatment approaches.
- Current guidelines and emerging targets highlight the shift toward personalized management of this autoimmune condition.

## Abstract

Graves’ ophthalmopathy (GO), also known as thyroid eye disease (TED), is the most common extrathyroidal manifestation of Graves’ disease and a leading cause of visual morbidity. The disease primarily affects the orbital tissue and is characterized by inflammation, expansion of extraocular muscles, and remodeling of orbital fat, resulting in proptosis, diplopia, and even vision loss. Active GO poses significant therapeutic challenges and often requires prompt intervention to preserve visual function and improve quality of life. Over the past decade, considerable progress has been made in understanding the immunopathogenesis of GO, leading to the development of targeted pharmacological therapies that extend beyond traditional systemic corticosteroids. This review summarizes recent advances in the drug therapy of active GO, focusing on novel immunomodulators, biological agents such as monoclonal antibodies targeting CD20, IL-6 R, and insulin-like growth factor-1 receptor (IGF-1R), and evolving treatment strategies based on disease activity and severity. We also discuss current clinical practice guidelines, emerging therapeutic targets under investigation, and future perspectives in the individualized management of this vision-threatening autoimmune condition.